Home › Funds › NAN FUNG TRINITY (HK) Ltd › BBIO
NAN FUNG TRINITY (HK) Ltd position in BBIO
BRIDGEBIO PHARMA INC · Health Care
NAN FUNG TRINITY (HK) Ltd reported holding 219,215 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$14.4M, representing 1.38% of its reported portfolio and ranking #28 among its reported holdings. NAN FUNG TRINITY (HK) Ltd has disclosed BBIO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How NAN FUNG TRINITY (HK) Ltd's BBIO position evolved
NAN FUNG TRINITY (HK) Ltd first disclosed a stake in BBIO in Q4 2025 at 110,100 shares (US$8.4M). The position peaked in Q2 2026 at 219,215 shares, worth US$16.3M. Across 4 filings, NAN FUNG TRINITY (HK) Ltd increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 219,215 shares valued at US$14.4M. Notable position changes include a 99% increase in Q1 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 110.10K | $8.42M | New |
| Q1 2026 | 219.22K | $16.28M | Add |
| Q2 2026 | 219.22K | $16.33M | Hold |
| Q3 2026 | 219.22K | $14.42M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBIO and 13F data
BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 41 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBIO
- Jupiter Topco LLC 14.11M sh · $1.05B · Q2 2026
- Janus Henderson Group 13.18M sh · $978.61M · Q1 2026
- Farallon Capital Management 10.74M sh · $800.14M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 10.74M sh · $800.14M · Q2 2026
- Viking Global Investors 9.95M sh · $741.02M · Q2 2026
- VIKING GLOBAL INVESTORS LP 9.95M sh · $741.02M · Q2 2026
- Aisling Capital Management LP 3.09M sh · $203.30M · Q3 2026
- SC US (TTGP), LTD. 1.86M sh · $138.56M · Q2 2026
- CAPSTONE INVESTMENT ADVISORS, LLC 69.87M sh · $124.49M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.55M sh · $115.31M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 1.37M sh · $102.27M · Q2 2026
- Hood River Capital Management LLC 1.35M sh · $100.36M · Q2 2026
More on NAN FUNG TRINITY (HK) Ltd
FAQ
How long has NAN FUNG TRINITY (HK) Ltd held BBIO?
NAN FUNG TRINITY (HK) Ltd has disclosed BBIO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is NAN FUNG TRINITY (HK) Ltd's current position in BBIO?
As of Q3 2026, NAN FUNG TRINITY (HK) Ltd holds 219.22K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $14.42M, representing 1.38% of its reported portfolio and ranking #28.
Has NAN FUNG TRINITY (HK) Ltd been buying or selling BBIO?
In the latest 13F filing (Q3 2026), NAN FUNG TRINITY (HK) Ltd held unchanged its position in BBIO. The position peaked in Q2 2026 at 219.22K shares.
Which other funds hold BBIO?
Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.